NCT00018538 is a Phase 2 clinical trial of calcifidiol in Prostate Cancer, sponsored by US Department of Veterans Affairs.

Who is sponsoring NCT00018538?

NCT00018538 is sponsored by US Department of Veterans Affairs.

What drugs are being tested in NCT00018538?

Interventions in NCT00018538: calcifidiol.

What condition does NCT00018538 study?

NCT00018538 studies Prostate Cancer.

Is NCT00018538 still recruiting?

NCT00018538 is currently completed. Last updated 20 January 2009.

Last reviewed 2009-01-20 · How we verify

NCT00018538

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Calcifidol Therapy in Men With Cancer

Completed Phase 2 Last updated 20 January 2009

What this trial tests

Phase 2 trial testing calcifidiol in Prostate Cancer. Completed in 1 September 2002.

Timeline

1 October 1999

1 September 2002

Quick facts

Lead sponsor	US Department of Veterans Affairs
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 October 1999
Estimated completion	1 September 2002
Sites	1 location across United States

Drugs / interventions tested

calcifidiol — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

US Department of Veterans Affairs

Who can join

Eligibility, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prostate cancer is a common occurrence in the aging population, with one in ten men destined to develop the disease. 40% of patients with prostate cancer experience a recurrence after definitive treatment. This study addresses the as-yet unresolved problem of the optimal management of early recurrence as manifested by increase in the accepted marker for this disease, PSA. Vitamin D, an agent with cell-differentiating properties, has been shown to inhibit angiogenesis and cause differentiation of prostate cancer cells in the laboratory and to affect PSA favorably in clinical studies of patients with advanced prostate cancer. This study will assess the effects of vitamin D in patients with sub-clinical biochemical relapses of prostate cancer as indicated by rising PSA but low tumor burdens, with the potential for developing an approach to this problem that will delay or prevent progression.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions.
Paller CJ, Antonarakis ES. · · 2013 · cited 167× · PMID 23416859
Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?
Patrikidou A, Zilli T, Baciarello G, Terisse S, et al · · 2021 · cited 7× · PMID 34707693 · DOI 10.1177/17588359211051870

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other US Department of Veterans Affairs trials

Trials by the same sponsor.

NCT06068699 — Postcards to Improve Remote Monitoring Adherence Among Veterans · NA · completed
NCT00262496 — Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach. · Phase 2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00018538 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by US Department of Veterans Affairs
Last refreshed: 20 January 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00018538.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing